Posted by Michael Wonder on 11 Dec 2024
Health Canada approves Celltrion’s Omlyclo (CT-P39), the first and only omalizumab biosimilar in Canada
9 December 2024 - Omlyclo (CT-P39) is the first and only omalizumab biosimilar referencing Xolair approved in Canada to treat multiple allergic diseases including chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps.
Celltrion today announced that Health Canada has approved Omlyclo, a biosimilar referencing Xolair.
